Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.
Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, Bisch JA, Richardson T, Jaros M, Wijngaard PLJ, Kastelein JJP; ORION-10 and ORION-11 Investigators. Ray KK, et al. Among authors: kallend d. N Engl J Med. 2020 Apr 16;382(16):1507-1519. doi: 10.1056/NEJMoa1912387. Epub 2020 Mar 18. N Engl J Med. 2020. PMID: 32187462 Clinical Trial.
Inclisiran and cardiovascular events: a patient-level analysis of phase III trials.
Ray KK, Raal FJ, Kallend DG, Jaros MJ, Koenig W, Leiter LA, Landmesser U, Schwartz GG, Lawrence D, Friedman A, Garcia Conde L, Wright RS; ORION Phase III investigators. Ray KK, et al. Among authors: kallend dg. Eur Heart J. 2023 Jan 7;44(2):129-138. doi: 10.1093/eurheartj/ehac594. Eur Heart J. 2023. PMID: 36331326 Free PMC article.
Effect of inclisiran on lipids in primary prevention: the ORION-11 trial.
Ray KK, Kallend D, Leiter LA, Raal FJ, Koenig W, Jaros MJ, Schwartz GG, Landmesser U, Garcia Conde L, Wright RS; ORION-11 Investigators. Ray KK, et al. Among authors: kallend d. Eur Heart J. 2022 Dec 21;43(48):5047-5057. doi: 10.1093/eurheartj/ehac615. Eur Heart J. 2022. PMID: 36331315 Free PMC article. Clinical Trial.
Corrigendum to "Evaluation of the distribution and excretion of [14C]-inclisiran following single subcutaneous administration in cynomolgus monkeys" [Toxicology and Applied Pharmacology 443 (2022) 115978].
Lehoux D, Far AR, Kallend D, Wijngaard PLJ, Zerler B. Lehoux D, et al. Among authors: kallend d. Toxicol Appl Pharmacol. 2022 Sep 15;451:116144. doi: 10.1016/j.taap.2022.116144. Epub 2022 Jul 1. Toxicol Appl Pharmacol. 2022. PMID: 35780943 No abstract available.
62 results